In pharmaceuticals, working effectively with contract development and manufacturing organizations (CDMOs) is an art as well as a science. This e-book begins by giving advice to emerging pharma companies on how selecting a CDMO is like “betting the house” in a card game. The next article shares how a CDMO addresses two critical areas — CMC support and quality assurance — can often dictate how effective a CDMO can be in supporting and accelerating the timeline for the drug sponsor’s drug development program through commercial manufacturing. The third article shares recommendations on how to find common ground with your CDMO when assessing risks, and it also provides tips to facilitate trust.
Once you’ve selected your CDMO and begun working with them, you can transform your relationship into one that sets all your manufacturing “red lights” to “green lights” for pipeline acceleration and speeder time to market. Shared qualification audits add to the win-win relationship. Another article shares a better path for CDMO relationships as the pandemic continues. The last article in the e-book highlights post-COVID supply chain opportunities and strategies for both pharmas and CDMOs.